To date, approved ICIs for the frontline treatment of metastatic NSCLC include PD-1 inhibitors (pembrolizumab, nivolumab, and cemiplimab), PD-L1 inhibitors (atezolizumab), and CTLA-4 inhibitors (ipilimumab) [6]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.